- American City Business Journals•54 minutes ago
United Therapeutics Corp. (UTHR) blames increasing competition in the pulmonary arterial hypertension space for its lower-than-expected revenue last year, CEO Martine Rothblatt told analysts Wednesday. During the Silver Spring-based company's fourth-quarter earnings call, Rothblatt said there has been weaker growth for some of its drugs — Orenitram, Tyvaso and Remodulin. Patients are sticking with alternative therapies, such as a combination of Adcirca with Letairis, longer than expected before switching to its products, she said.
- MarketWatch•2 hours ago
U.S. stocks retreat modestly on Thursday, pulling back from intraday records as technology stocks struggle amid persistent concerns about lofty valuations and the prospects for fiscal stimulus a day after ...
- Business Wire•2 hours ago
Pfizer Inc. today announced the election of Ronald E. Blaylock to its Board of Directors, effective immediately. Mr. Blaylock was also appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board.
PFE : Summary for Pfizer, Inc. Common Stock - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||33.58 - 34.12|
|52 Week Range||28.74 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||29.04|
|Dividend & Yield||1.28 (3.81%)|
|1y Target Est||N/A|